FDA Drug Labeling: OTC Drug Facts Panel vs Prescription Drug Labeling Requirements

Drug labeling in the United States follows prescriptive formats that differ fundamentally based on whether the product is an over-the-counter drug or a prescription drug. OTC drug labeling is built around the Drug Facts panel — a standardized, consumer-facing format designed to help patients make informed self-medication decisions. Prescription drug labeling is built around the Physician Labeling Rule (PLR) format — also known as the Highlights of Prescribing Information — a comprehensive, clinician-facing document that includes detailed pharmacological, clinical, and safety information. Foreign drug manufacturers must determine which format applies to their product and ensure that the labeling is prepared in the correct format before the product enters the US market, because incorrect labeling format is a misbranding violation that will result in import refusal.

OTC Drug Facts panel under 21 CFR 201.66

Every OTC drug sold in the United States must carry a Drug Facts panel on its immediate container or outer packaging, formatted in accordance with 21 CFR 201.66. The Drug Facts panel has a mandatory structure that must appear in the following order: the heading 'Drug Facts' in a specified typeface and size, the active ingredient(s) and their concentration or amount per dosage unit, the purpose (therapeutic category) of each active ingredient, the uses (indications) for which the product is marketed, a warnings section that includes any monograph-specific warnings plus standard warnings (such as 'Keep out of reach of children,' 'If pregnant or breast-feeding, ask a health professional before use,' and allergy alerts), directions for use including dosage by age group, other information (such as storage conditions), and inactive ingredients listed in alphabetical order.

The format specifications are highly detailed. The Drug Facts heading must appear in white text on a black background bar, or in an equivalent high-contrast format. The text must use a minimum type size of 6 point with adequate leading (line spacing). Bullets must separate individual items within sections. The panel must be enclosed in a hairline box with specific margins. Foreign manufacturers who attempt to adapt labeling from another market — such as EU PIL (Patient Information Leaflet) or Japanese package insert format — into the Drug Facts format will find that the content, structure, and typographic requirements are fundamentally different and cannot be achieved through simple reformatting.

Prescription drug labeling under the Physician Labeling Rule

Prescription drug labeling follows the format established by the Physician Labeling Rule (PLR) under 21 CFR 201.56 and 201.57, finalized in 2006. The PLR format requires a structured document that begins with 'Highlights of Prescribing Information' — a concise summary of the most important information about the drug — followed by a full prescribing information section with 17 standard sections including indications and usage, dosage and administration, dosage forms and strengths, contraindications, warnings and precautions, adverse reactions, drug interactions, use in specific populations (pregnancy, lactation, pediatric use, geriatric use), overdosage, description, clinical pharmacology, nonclinical toxicology, clinical studies, how supplied/storage and handling, and patient counseling information.

Differences between US and international drug labeling

Foreign manufacturers frequently attempt to use their existing international drug labeling as the basis for US labeling, but the differences between US and international formats are substantial. EU labeling follows the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL) format required by EMA. Japanese labeling follows PMDA requirements. Neither format maps directly onto the US Drug Facts panel or PLR format. The content requirements differ (the US requires specific warning language that may not appear in international labeling), the structure differs (the US Drug Facts panel has a rigid section order that other formats do not follow), and the typographic specifications differ. Foreign manufacturers should plan for complete labeling development for the US market rather than attempting to adapt existing international labeling.

SPL format for electronic labeling submissions

All drug labeling must be submitted to the FDA in Structured Product Labeling (SPL) format as part of the drug listing process. The SPL file is an XML document that contains the full text of the labeling in a structured, machine-readable format. For OTC drugs, the SPL includes the Drug Facts panel content. For prescription drugs, the SPL includes the full PLR-format prescribing information. The SPL file is submitted through FDA's ESG system and is processed into the DailyMed database, which serves as the authoritative repository for current drug labeling in the United States. The SPL submission must be updated whenever the labeling changes, and updated labeling must be submitted at the next semi-annual drug listing update (June or December).

How FDABridge handles drug labeling compliance

FDABridge manages drug establishment registration and drug product listing for foreign manufacturers, including SPL file preparation and submission. Our team ensures your drug labeling content is accurately captured in SPL format and submitted through FDA's electronic systems. Visit fdabridge.com/drug to see our drug registration services or fdabridge.com/contact to discuss your drug labeling needs.